drugset / Trial / NCT01365104

Modulation of Cerebral Blood Flow Using Iron Chelators

NCT01365104

RandomizedCrossoverTriple-blindPrevention

Summary

The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

Timeline

Start
2008-03
Primary completion
2012-06
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferoxamine Other / unclassified 60 mg/kg Intravenous

Indications